SCHEMBL5524915

SCHEMBL5524915

COc1cccc(CNC(=O)[C@H]2CC[C@@H](Nc3nc(N(C)C)c4cc(F)c(F)cc4n3)CC2)c1

nearest known ligand 0.50

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 7/20 0.50
ADRA2A P08913 6/20 0.50
HTR1A P08908 1/20 0.48
ADRA1A P35348 1/20 0.48
HRH1 P35367 1/20 0.48
HTR2B P41595 1/20 0.48
NPY5R Q15761 1/20 0.48
PKM P14618 4/20 0.47
ALDH1A1 P00352 3/20 0.45
LMNA P02545 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2C9 P11712 1/20 0.45
HSD17B10 Q99714 1/20 0.45
TSHR P16473 1/20 0.44
CHKA P35790 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5524920 1.00 MCHR1 (0.50) MCHR1ADRA2AHTR1AADRA1AHRH1
SCHEMBL5529401 0.92 MCHR1 (0.53) MCHR1ADRA2AHTR1AADRA1AHRH1
SCHEMBL5529407 0.92 MCHR1 (0.53) MCHR1ADRA2AHTR1AADRA1AHRH1
SCHEMBL5530648 0.91 MCHR1 (0.50) MCHR1ADRA2AHTR1AADRA1AHRH1
SCHEMBL5527692 0.91 MCHR1 (0.50) MCHR1ADRA2AHTR1AADRA1AHRH1
SCHEMBL4204964 0.90 MCHR1 (0.62) MCHR1ADRA2AHTR1AADRA1AHRH1
SCHEMBL4204958 0.90 MCHR1 (0.62) MCHR1ADRA2AHTR1AADRA1AHRH1
SCHEMBL5530040 0.89 MCHR1 (0.57) MCHR1ADRA2AHTR1AADRA1AHRH1
SCHEMBL5530046 0.89 MCHR1 (0.57) MCHR1ADRA2AHTR1AADRA1AHRH1
SCHEMBL5519633 0.89 MCHR1 (0.49) MCHR1ADRA2AHTR1AADRA1AHRH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070010671-A1 Novel quinazoline derivatives and methods of treatment related to the use thereof ARENA PHARMACEUTICALS, INC. 2007-01-11 US claimed
US-20070010671-A1 Novel quinazoline derivatives and methods of treatment related to the use thereof ARENA PHARMACEUTICALS, INC. 2007-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010671-A1 Novel quinazoline derivatives and methods of treatment related to the use thereof MCHR1, GPR119, MCHR2 MCHR1 1/4885ADRA2A 103/4885HTR1A 61/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.